Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up

阿列克替尼 克里唑蒂尼 医学 间变性淋巴瘤激酶 肺癌 内科学 肿瘤科 阶段(地层学) 临床终点 胃肠病学 临床试验 古生物学 恶性胸腔积液 生物
作者
Chao Zhang,Si‐Yang Maggie Liu,Ben‐Yuan Jiang,Zhiyong Chen,Li‐Xu Yan,Zhen‐Bin Qiu,Jun‐Tao Lin,Yang Xue-ning,Yuping Wu,Hao Sun,Wen‐Zhao Zhong
出处
期刊:Chinese Medical Journal [Lippincott Williams & Wilkins]
标识
DOI:10.1097/cm9.0000000000003798
摘要

Abstract Background: Despite increased response and long-term benefit of anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC) harboring ALK -fusion, the role of induction ALK-TKIs in locally advanced NSCLC remained poorly investigated. This study aimed to demonstrate the short-term and long-term efficacy of ALK-targeted induction therapy in stage III lung cancer. Methods: We consecutively collected data of patients from Guangdong Lung Cancer Institute since 2016, and those who were pathologically confirmed stages IIIA–IIIB NSCLC treated with induction ALK-TKIs initially were eligible for subsequent analysis. Patients’ clinicopathological features as well as therapeutic management were fully reviewed. Analysis of longitudinal single-cell RNA sequencing from patients treated with alectinib were performed. Fisher’s exact test was used to compare two categorical variable and Kaplan–Meier is applied for survival curve with estimation for median and 95% confidence interval (CI) value if available. Results: Forty stage III NSCLC patients treated with either alectinib or crizotinib were enrolled. Among those who had surgery, all patients had R0 resection without postoperative radiotherapy. Only two patients suffered grade 2 postoperative complications in terms of Clavien–Dindo score. Induction alectinib showed numerically superior pathological response compared with crizotinib with both major pathological response (MPR) (11/17, 65% vs. 6/13, 46%, P = 0.46) and complete pathological response (pCR) (6/17, 35% vs. 2/13, 15%, P = 0.41). Patients who received induction alectinib had significantly longer PFS (not reached [NR] vs. 17.9 months, P <0.001) and numerically improved overall survival (NR vs. NR, P = 0.092) compared with crizotinib. Brain metastasis remained the most common recurrent pattern after induction ALK-TKIs. Longitudinal single-cell RNA sequencing revealed increased tumor stemness and induced a more suppressive immune microenvironment in the residual tumor while highly inflamed microenvironment along with low infiltrating regulatory T cell and exhausted T cell was observed in resected specimens which achieved pCR. Conclusion: Induction ALK-TKIs provided a clinically efficient and well-tolerated therapeutic strategy in locally advanced ALK-positive NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Aaaaa完成签到,获得积分10
1秒前
1秒前
科研发布了新的文献求助30
1秒前
坚定的蜗牛完成签到,获得积分10
2秒前
小二郎的应助被精分的猫采纳,获得10
2秒前
石幼蓉发布了新的文献求助10
2秒前
cjk发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
壮观雁易发布了新的文献求助10
4秒前
4秒前
上官若男的应助被大白采纳,获得10
5秒前
exile发布了新的文献求助10
6秒前
6秒前
6秒前
搜集达人的应助被小鱼采纳,获得10
6秒前
陈默发布了新的文献求助10
6秒前
Yuan88发布了新的文献求助10
7秒前
8秒前
8秒前
萤火虫完成签到 ,获得积分10
8秒前
369ninja发布了新的文献求助10
8秒前
Lucas的应助被drizzle采纳,获得10
8秒前
9秒前
9秒前
现代老鼠完成签到,获得积分10
9秒前
李Tt发布了新的文献求助10
10秒前
Yuan88发布了新的文献求助10
10秒前
YR完成签到 ,获得积分10
11秒前
ding的应助被卷卷采纳,获得10
11秒前
Fanzhea完成签到,获得积分10
11秒前
lhm完成签到,获得积分10
11秒前
11秒前
小蘑菇的应助被腼腆的立诚采纳,获得10
11秒前
琛哥物理完成签到,获得积分10
12秒前
12秒前
season6669完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184220
求助须知:如何正确求助?哪些是违规求助? 9573266
关于积分的说明 21830447
捐赠科研通 7781246
什么是DOI,文献DOI怎么找? 3434248
关于科研通互助平台的介绍 2558373
邀请新用户注册赠送积分活动 2480784